Medtronic stock: Contego deal expands vascular portfolio
Published on 11/18/2026 at 17:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMedtronic expands vascular portfolio
- Medtronic plans to acquire Contego Medical to broaden its carotid and peripheral thrombectomy portfolio.
- The transaction is expected to be minimally dilutive to adjusted earnings per share in fiscal 2027 and fiscal 2028.
- Completion is targeted for Medtronic's fiscal third quarter, subject to customary closing conditions.
Medtronic said on Monday, November 16, that it intends to acquire Contego Medical, a privately held medical-device company focused on carotid artery disease and peripheral thrombectomy. The announcement was made in a Medtronic press release.
Deal targets carotid therapies
The planned transaction adds Contego's FDA-approved Neuroguard IEP Direct System and Excipio thrombectomy devices to Medtronic's portfolio. The company said the products expand its offerings for carotid and peripheral vascular disease and build on an exclusive U.S. distribution agreement announced in January 2025.
Medtronic expects to complete the transaction in the third quarter of its fiscal year, subject to customary closing conditions. The purchase price is 380 million US dollars, with potential payments after closing.
Limited earnings impact expected
Management expects the acquisition to be minimally dilutive to adjusted earnings per share in fiscal 2027 and fiscal 2028, before becoming neutral to accretive thereafter. That framing puts the near-term emphasis on portfolio expansion rather than an immediate earnings contribution.
Medtronic stock traded at 91.26 euros on Lang & Schwarz at 17:05 CET on Wednesday, November 18.
Medtronic company facts
- Company: Medtronic plc
- ISIN: IE00BTN1Y115
- NYSE ticker: MDT
- Lang & Schwarz quote: 91.26 euros at 17:05 CET on November 18, 2026
Investors will next look to the company's fiscal second-quarter results, scheduled for November 24, 2026, for evidence that portfolio growth is carrying through to the broader business.
Current market reports are available through Current market reports.
More news and analyses on Medtronic stock.
